Form 4: Castle Biosciences CCO Exercises RSUs, Sells for Tax

Castle Biosciences' Chief Commercial Officer, Tobin W. Juvenal, exercised Restricted Stock Units and subsequently sold shares for tax withholding purposes.

Summary

• Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences Inc. (CSTL), reported multiple transactions involving the company's common stock.
• On December 9, 2025, Juvenal acquired 15,961 shares of common stock through the exercise of Restricted Stock Units (RSUs).
• Concurrently, 6,441 shares were disposed of at a price of $38.25 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Juvenal's direct beneficial ownership stood at 96,345 shares.
• On December 10, 2025, an additional 6,170 shares of common stock were acquired from the exercise of RSUs.
• On the same day, 2,490 shares were disposed of at $38.02 per share for tax withholding.
• After these transactions, Juvenal's direct beneficial ownership increased to 100,025 shares.
• The acquired shares on December 9, 2025, were part of a 63,844 RSU grant from December 9, 2022, vesting in four equal installments.
• The acquired shares on December 10, 2025, were part of a 24,679 RSU grant from December 10, 2021, also vesting in four equal installments.
• The reported beneficial ownership also includes 2,230 shares previously held by the Tobin W and Susan M Juvenal Family Revocable Trust, which were distributed directly to Juvenal on February 5, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive to neutral. The exercise of RSUs is a positive sign of an executive realizing value from their compensation, indicating continued engagement. The subsequent sale for tax purposes is a routine, neutral event and does not reflect a negative outlook on the company.

Positives

• The exercise of Restricted Stock Units indicates the Chief Commercial Officer is realizing value from his compensation package, aligning his interests with shareholders.
• The increase in direct beneficial ownership to 100,025 shares after the transactions demonstrates continued significant personal investment in the company.

Negatives

• The disposition of 6,441 shares at $38.25 and 2,490 shares at $38.02, while for tax withholding, reduces the officer's direct equity stake in the company.

Risks

• The routine nature of these transactions, often pre-scheduled, means they typically do not signal new risks or opportunities for the company beyond standard executive compensation practices.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.

Industry Context

This insider transaction report is a routine disclosure of executive compensation realization and does not provide specific insights into broader industry trends or competitive landscape. Such transactions are common across publicly traded companies as part of executive equity incentive plans.

Related Party Transactions

• The reported beneficial ownership includes 2,230 shares previously held by the Tobin W and Susan M Juvenal Family Revocable Trust, which were distributed directly to the Reporting Person on February 5, 2025.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect executive compensation. They do not indicate a significant change in company fundamentals or strategy that would directly impact shareholder value beyond the standard implications of insider ownership.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the exercise of Restricted Stock Units and subsequent tax-related sales. Such events are typically pre-scheduled and do not provide new fundamental information about the company's operational performance, strategic direction, or future outlook. Therefore, it does not warrant a change in investment recommendation, and a 'hold' stance is appropriate as there's no strong buy or sell signal from this specific filing.

Keywords

CSTL, Castle Biosciences, Insider Transaction, Form 4, Restricted Stock Units, RSU, Executive Compensation, Stock Sale, Tax Withholding